Cargando…

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma

PURPOSE: Considering the increased cancer patient survivorship, the focus is now on addressing the impacts of treatment on quality of life. In young people, altered reproductive function is a major issue and its effects in young males are largely neglected by novel research. To improve clinician awa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amin, M. S. A., Brunckhorst, O., Scott, C., Wrench, D., Gleeson, M., Kazmi, M., Ahmed, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084804/ https://www.ncbi.nlm.nih.gov/pubmed/32944834 http://dx.doi.org/10.1007/s12094-020-02483-8

Ejemplares similares

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy
por: Jayabose, Somasundaram, et al.
Publicado: (2016)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
por: Suwanban, Tawatchai, et al.
Publicado: (2023)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

P016: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
por: Dragičević, Ida Hude, et al.
Publicado: (2022)

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron D., et al.
Publicado: (2021)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
por: Subbiah, Vivek, et al.
Publicado: (2007)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
por: Yonezawa, Ryo, et al.
Publicado: (2023)

Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)
por: Hess, Patrick P., et al.
Publicado: (2022)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
por: Cotteret, Camille, et al.
Publicado: (2020)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
por: Russell, James, et al.
Publicado: (2021)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
por: Chakraborty, Rajshekhar, et al.
Publicado: (2015)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
por: DeBoer, Rebecca J., et al.
Publicado: (2020)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
por: Marková, Jana, et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
por: Dorokhina, Elena, et al.
Publicado: (2022)

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021)

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
por: Pavlovsky, A., et al.
Publicado: (2022)

Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron Daniel, et al.
Publicado: (2020)

Fertility in female survivors of Hodgkin's lymphoma
por: Biasoli, Irene, et al.
Publicado: (2012)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
por: Martinez, Celia, et al.
Publicado: (2023)

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
por: Ciccarone, Mariavita, et al.
Publicado: (2023)

The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy
por: Brusamolino, Ercole, et al.
Publicado: (2012)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cilhlqskos83rpp184pq884nak